Ubs Group Ag Jounce Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$0.9 - $1.85 $8,283 - $17,027
9,204 Added 77.82%
21,031 $38,000
Q4 2022

Feb 08, 2023
BUY
$0.64 - $1.99 $7,421 - $23,076
11,596 Added 5019.91%
11,827 $13,000
Q3 2022

Nov 10, 2022
SELL
$2.73 - $4.92 $72,497 - $130,655
-26,556 Reduced 99.14%
231 $1,000
Q2 2022

Aug 10, 2022
BUY
$2.8 - $7.67 $39,760 - $108,914
14,200 Added 112.81%
26,787 $82,000
Q1 2022

May 16, 2022
SELL
$6.01 - $8.54 $63,044 - $89,584
-10,490 Reduced 45.46%
12,587 $85,000
Q4 2021

Feb 14, 2022
BUY
$7.11 - $9.64 $83,563 - $113,298
11,753 Added 103.79%
23,077 $193,000
Q3 2021

Nov 15, 2021
SELL
$5.04 - $8.73 $35,264 - $61,083
-6,997 Reduced 38.19%
11,324 $84,000
Q2 2021

Aug 13, 2021
SELL
$6.58 - $10.66 $6,987 - $11,320
-1,062 Reduced 5.48%
18,321 $125,000
Q1 2021

May 12, 2021
BUY
$6.73 - $13.87 $102,834 - $211,933
15,280 Added 372.41%
19,383 $199,000
Q4 2020

Feb 11, 2021
BUY
$6.37 - $10.33 $21,237 - $34,440
3,334 Added 433.55%
4,103 $29,000
Q3 2020

Nov 12, 2020
SELL
$4.58 - $10.95 $21,484 - $51,366
-4,691 Reduced 85.92%
769 $6,000
Q2 2020

Jul 31, 2020
SELL
$4.17 - $7.58 $38,122 - $69,296
-9,142 Reduced 62.61%
5,460 $38,000
Q1 2020

May 01, 2020
SELL
$2.91 - $8.7 $16,857 - $50,399
-5,793 Reduced 28.4%
14,602 $69,000
Q4 2019

Feb 14, 2020
BUY
$2.81 - $9.21 $22,241 - $72,897
7,915 Added 63.42%
20,395 $178,000
Q3 2019

Nov 14, 2019
BUY
$3.33 - $4.93 $31,798 - $47,076
9,549 Added 325.79%
12,480 $41,000
Q2 2019

Aug 14, 2019
BUY
$4.3 - $6.73 $2,700 - $4,226
628 Added 27.27%
2,931 $15,000
Q1 2019

May 14, 2019
SELL
$3.43 - $6.87 $15,088 - $30,221
-4,399 Reduced 65.64%
2,303 $14,000
Q4 2018

Feb 14, 2019
BUY
$2.69 - $6.71 $6,620 - $16,513
2,461 Added 58.03%
6,702 $22,000
Q3 2018

Nov 14, 2018
BUY
$6.5 - $8.37 $25,941 - $33,404
3,991 Added 1596.4%
4,241 $28,000
Q2 2018

Aug 14, 2018
SELL
$7.27 - $21.88 $7,858 - $23,652
-1,081 Reduced 81.22%
250 $2,000
Q1 2018

May 15, 2018
BUY
$13.4 - $28.4 $227 - $482
17 Added 1.29%
1,331 $30,000
Q4 2017

Feb 14, 2018
BUY
$12.52 - $17.82 $11,894 - $16,929
950 Added 260.99%
1,314 $17,000
Q3 2017

Nov 14, 2017
BUY
$11.17 - $16.99 $4,065 - $6,184
364 New
364 $6,000
Q2 2017

Aug 14, 2017
SELL
N/A
-1,110 Closed
0 $0
Q1 2017

Nov 14, 2017
BUY
N/A
1,110
1,110 $24,000

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email